Statistics for Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector

Total visits

views
Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector 26

Total visits per month

views
December 2024 0
January 2025 0
February 2025 0
March 2025 2
April 2025 0
May 2025 0
June 2025 0

File Visits

views
MPH_COMH7175A_1946476_03.06.2023.pdf 105

Top country views

views
South Africa 21
Tanzania 2
Norway 1

Top city views

views
Johannesburg 17
Dar es Salaam 2
Lenasia 2
Pretoria 1